Allendale, NJ, Feb 1, 2012; Lonza’s late 2011 acquisition of Arch Chemicals has brought new antimicrobial solutions to Lonza’s portfolio of polymer additives, including Zinc Omadine™, Vanquish™ 100 and Vanquish™ SL10 antimicrobial products. These powerful solutions inhibit the growth of mold, mildew and bacteria in a wide array of plastic applications, from flexible vinyl shower curtains and SBR bath mats to carpeting and foam bedding products.
Oxybisphenoxarsine (OBPA) will not be supported through the European BPD process, consequently customers are looking for an alternative to this widely used product. Lonza now offers unique products specifically designed to replace OBPA based antimicrobials.
Stephen Wood, Commercial Development Manager for Lonza’s Materials Protection business, emphasizes that the advanced antimicrobial technology from Arch complements Lonza’s traditional strengths in lubricants, anti-fogs, anti-stats and processing aids for polymer products.
“With the addition of Arch’s proven, registered antimicrobial solutions, Lonza Microbial Control can now offer the plastics industry a stronger portfolio of products along with advanced microbiological and analytical chemistry technical services to meet their growing needs,” Mr. Wood said. Within the Materials Protection market, Lonza Microbial Control is an innovative leader in antimicrobial actives and formulated additives for use in plastics, emulsions, textiles, metalworking fluids, paints, coatings and other building materials.
This acquisition has created the world’s leading microbial control business -- Lonza Microbial Control. Today Lonza offers:
- one of the broadest portfolios of registered antimicrobial actives and related end-use formulations in the world;
- a greatly expanded global infrastructure of production, customer-support and R&D facilities, including a new world-class Innovation and Technology Center in Alpharetta, GA;
- additional resources to invest in developing new solutions in concert with customers; and
- increased global expertise in navigating complex regulatory environments.
“This is an exciting time for both Lonza and our customers,” Mr. Wood asserts.
Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bio-products which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets. Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange.
In 2010, the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com.
Lonza Group Ltd
Tel +1 201 316 9413
Fax +1 201 696 3533
Lonza Microbial Control
N.A. Commercial Development Manager
90 Boroline Road Allendale, NJ 07401
Tel 1 201 316 9461
Fax 1 201 696 3448